Results 211 to 220 of about 67,755 (267)

Rituximab in B-Cell chronic lymphocytic leukemia

Seminars in Oncology, 2003
The monoclonal anti-CD20 antibody rituximab exerts its antitumor activity through a variety of mechanisms, including acting against the cellular defects in apoptosis that give rise to B-chronic lymphocytic leukemia (B-CLL). Phase II clinical studies demonstrated that rituximab, given weekly as a single agent, exhibits significantly less activity in B ...
Thomas S, Lin, Margaret S, Lucas, John C, Byrd   +2 more
openaire   +2 more sources

Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia

Clinical Lymphoma, 2004
Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in the Western hemisphere.1 In this disease, a clonal proliferation of neoplastic B lymphocytes accumulates in bone marrow, blood, lymph nodes, liver, and spleen. According to the World Health Organization (WHO) classification, B-cell CLL is a mature (peripheral) B-cell neoplasm ...
Ilan, Shapira, Michael L, Grossbard
openaire   +2 more sources

Histopathology of B-cell chronic lymphocytic leukemia

Hematology/Oncology Clinics of North America, 2004
Histologic and immunohistologic findings of B-cell chronic lymphocytic leukemia/small lymphocytic leukemia are revised in the light of the more recent knowledge on the pathobiology of the disease. The guidelines for the optimal handling of the bioptic samples are provided. The relevance of the examination of trephines and surgical specimens is outlined
PILERI, STEFANO, SABATTINI, ELENA, AGOSTINELLI, CLAUDIO, BODEGA L, ROSSI M, ZINZANI, PIER LUIGI, MARAFIOTI, TERESA   +6 more
openaire   +2 more sources

Chronic Myelomonocytic Leukemia Coexisting with B-cell Chronic Lymphocytic Leukemia

Leukemia & Lymphoma, 2003
Coexistence of B-cell chronic lymphocytic leukemia (B-CLL) and chronic myelomonocytic leukemia (CMML) is an unusal event, and to our knowledge, only four such cases have been reported in the literature. We report a 68-year-old white woman in whom these two diseases were diagnosed concomitantly.
Tadeusz, Robak, Halina, Urbańska-Ryś, Piotr, Smolewski, Ewa, Wawrzyniak, Anna, Korycka, Radzisław, Kordek, Jacek, Bartkowiak   +6 more
openaire   +2 more sources

Cutaneous manifestations of B-cell chronic lymphocytic leukemia

International Journal of Hematology, 2020
Chronic lymphocytic leukemia (CLL) is a malignant lymphoproliferative disease characterized by the accumulation of immature monoclonal B lymphocytes in blood cells, bone marrow, spleen and lymph nodes. This is the most common type of leukemia among the Caucasoid race.
Elena A. Morozova, Olga Yu. Olisova, Eugene A. Nikitin   +2 more
openaire   +2 more sources

B-cell function in patients with chronic lymphocytic leukemia

Klinische Wochenschrift, 1982
Using a reverse hemolytic protein A plaque assay, spontaneous and pokeweed mitogen (PWM)-induced immunoglobulin (Ig) secretion was determined in peripheral blood from 22 patients with B1-chronic lymphocytic leukemia (CLL), one patient with B2-CLL, and one patient with suppressor T-CLL. Diagnoses were established by cytological and histological criteria
G, Sieber, F, Herrmann, B, Enders, H, Rühl   +3 more
openaire   +2 more sources

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2008
A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL.We investigated 1520 subjects who were 62 to 80 ...
Andy C, Rawstron, Fiona L, Bennett, Sheila J M, O'Connor, Marwan, Kwok, James A L, Fenton, Marieth, Plummer, Ruth, de Tute, Roger G, Owen, Stephen J, Richards, Andrew S, Jack, Peter, Hillmen   +10 more
openaire   +2 more sources

Multidrug Resistance in B-Cell Chronic Lymphocytic Leukemia

Acta Haematologica, 2009
Multidrug resistance (MDR) was investigated in peripheral blood cells isolated from 40 patients with B cell chronic lymphocytic leukemia (B-CLL) and from 7 healthy volunteers, using a flow cytometric assay that detects cellular efflux of the fluorescent dye rhodamine 123 (Rh 123), which has been demonstrated to be transported from the cell by the P ...
I, Grulois, O, Fardel, B, Drenou, T, Lamy, P Y, Le Prisé, R, Fauchet   +5 more
openaire   +2 more sources

The normal counterpart to the chronic lymphocytic leukemia B cell

Best Practice & Research Clinical Haematology, 2007
Chronic lymphocytic leukemia (CLL) is characterized by the monoclonal expansion of small mature-looking B cells that accumulate in the blood, marrow, and lymphoid organs, and have a remarkable phenotypic homogeneity. By definition, CLL cells co-express CD5 and CD23 with faint to undetectable amounts of monoclonal surface immunoglobulins (sIg).
Caligaris Cappio F, GHIA , PAOLO PROSPERO   +1 more
openaire   +2 more sources

Alemtuzumab for B-cell chronic lymphocytic leukemia

Expert Review of Anticancer Therapy, 2008
Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleoside analogs.
openaire   +2 more sources